PATH vs SILO · P/E 19, rev $1.61B vs rev $72.1K
Uipath Inc (PATH) versus Silo Pharma Inc (SILO) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Silo Pharma Inc (SILO) is a biotechnology company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported SILO revenue for 2024-12-31 was $72.1K. Net income was -$4.4M. Revenue was up 0.0% from 2023-12-31 to 2024-12-31. SILO currently screens at market cap $4.4M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. SILO currently screens at market cap $4.4M.
Not investment advice. Open the PATH and SILO stock pages for the full models.
Not investment advice.